Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Conditions
Brief summary
In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.
Interventions
None listed
Sponsors
Sanofi
Dattoli Cancer Center and Brachytherapy Research Institute
Study design
Observational model
DEFINED_POPULATION
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
45 Years to 80 Years
Inclusion criteria
* Males age 45-80 years * Diagnosis of prostate cancer * Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation * Baseline AUA score\< or =12 * May be on antiandrogenand/or alpha reductase therapy * Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -
Exclusion criteria
* History of insulin-dependent diabetes * Uncontrolled hypertention * History of symptomtic hypotension (including syncope and dizziness) * Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention * Pre-existing prostatitis either continuous or intermittent * Concurrent use of any other anticholinergics * previous or concurrent usage of LHRH agonist
Countries
United States
Outcome results
None listed